Legal & Disputes
Wolf Popper Continues Xenon Pharmaceuticals Investor Investigation After 30.7% Stock Drop
By News Desk ·
Key takeaways
- Wolf Popper LLP is continuing an investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals common stock.
- Xenon's stock fell $17.60 per share, or 30.7%, to close at $39.75 on September 18, 2026, after it announced a voluntary pause in new patient enrollment in MDD and bipolar depression studies.
- Investors can contact Adam Savett at (212) 451-9655 or [email protected] to discuss the investigation.
Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. common stock, the firm said in a GlobeNewswire release dated October 20, 2026. Xenon's stock fell $17.60 per share, or 30.7%, to close at $39.75 on September 18, 2026, on very heavy trading volume.
Wolf Popper's Xenon Investigation
Xenon is a clinical-stage drug company developing azetukalner, formerly XEN1101, for neurological and psychiatric disorders, principally focal-onset seizures, major depressive disorder and bipolar depression. Azetukalner is a selective Kv7 potassium-channel opener designed to reduce excessive neuronal activity in the brain. In January 2025, Xenon announced the initiation of its Phase 3 X-NOVA2 trial, designed to enroll approximately 450 patients to evaluate a 20-mg dose of azetukalner against placebo for the treatment of MDD.
After the market closed on September 17, 2026, Xenon announced a voluntary pause in new patient enrollment in its ongoing clinical studies in MDD and bipolar depression following an analysis of neuropsychiatric adverse events in those studies. The next day, the stock closed at $39.75. Investors who suffered losses trading Xenon common stock and would like to discuss the investigation are encouraged to contact Adam Savett at (212) 451-9655 or asavett@wolfpopper.com.
Wolf Popper's Litigation Record
According to akta.pro company records, Wolf Popper is a New York-based litigation firm founded in 1945 with more than 80 years of experience advocating for investors, consumers and businesses in complex matters. The same records rank the firm among the Top 50 North American plaintiff law firms for securities-related class action settlements by ISS's Securities Class Action Services. Emily Madoff is managing partner, and the firm's headcount range is 11-50.
Other Securities Investigations
Pomerantz LLP is investigating claims on behalf of Securitize Corp. investors, GlobeNewswire reported on October 20, 2026. Pomerantz is also investigating Rent the Runway, Inc. investors, GlobeNewswire reported the same day, and Omeros Corporation, FinancialContent Business Page reported. Pomerantz is investigating Erasca, Inc. as well, FinancialContent Business Page reported on October 20, 2026.
Xenon's Enrollment Pause
Xenon announced the voluntary pause in new patient enrollment in its MDD and bipolar depression studies on September 17, 2026, after the market closed. The company has not stated a date for resuming enrollment.